Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Memorial Sloan Kettering Cancer Center at Basking Ridge
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States
- Memorial Sloan Kettering Westchester
Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Oct 2014
- Primary completion
- 22 Oct 2021
- Completion
- 22 Oct 2021
- Last update posted
- 26 Oct 2021
- Registered enrollment
- 16
- Registry id
- NCT02282371
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.